Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rizatriptan oral film - Nualtis

Next Previous
Drug Profile

Rizatriptan oral film - Nualtis

Alternative Names: INT 0008/2007; INT 0008/2008; INT0008; RHB-103; RIZAFILM; RIZAFILM VersaFilm; RIZAPORT; RIZAPORT® VersaFilm®; Rizatriptan benzoate - Nualtis

Latest Information Update: 10 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IntelGenx Corp.
  • Developer Exeltis; Nualtis; RedHill Biopharma
  • Class Antimigraines; Small molecules; Triazoles; Tryptamines
  • Mechanism of Action Serotonin 1B receptor agonists; Serotonin 1D receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Migraine

Highest Development Phases

  • Marketed Migraine

Most Recent Events

  • 31 Jan 2024 Launched for Migraine (In adolescents, In adults) in USA (PO)
  • 26 Sep 2023 Gensco® Pharma in partnership with IntelGenx plans the launch of Rizatriptan oral film in USA in the second quarter of 2024
  • 17 Apr 2023 IntelGenx in collaboration with its commercialization partner Gensco Laboratories intends to launch rizatriptan oral film for Migraine in USA (PO)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top